文献速递膀胱癌与上尿路尿路上皮癌

美国当前真实世界环境下新辅助化疗对肌层浸润性膀胱癌的疗效

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

基于美国国家癌症数据库(NCDB)2004至2012年间8732例接受根治性膀胱切除术的非转移性肌层浸润性尿路上皮癌患者,其中1619例(19%)接受新辅助化疗(NAC)。倾向评分加权后NAC与总生存无显著关联(HR 0.97;p=0.591),但pN0率更高(OR 5.03;p<0.001),且pN0率低于SWOG-8710试验(13% vs 38%)。作者认为需更好的选择标准以确定NAC获益人群。

要点

  • 美国真实世界数据显示,19%的肌层浸润性膀胱癌患者在接受根治性膀胱切除术前行新辅助化疗。
  • 倾向评分加权后,新辅助化疗与总生存无显著关联(HR 0.97;p=0.591)。
  • 新辅助化疗组pN0率更高(OR 5.03;p<0.001),但pN0率低于SWOG-8710试验(13% vs 38%)。

核心结论

  • 在美国当前普通泌尿外科实践中,校正不朽时间偏倚后,根治性膀胱切除术前新辅助化疗与单纯根治性膀胱切除相比未显示明确的生存优势。
  • 作者认为需要更好的选择标准以确定哪些患者将从根治性膀胱切除术前化疗中获益最多。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库(NCDB)识别2004至2012年间接受根治性膀胱切除术的非转移性肌层浸润性膀胱尿路上皮癌患者。
  • 共纳入8732例接受根治性膀胱切除术的患者,其中1619例(19%)接受新辅助化疗。
  • 主要终点为总生存(OS),采用里程碑分析校正不朽时间偏倚后以Cox回归比较;次要终点为pN0率、病理淋巴结阳性(pN+)率和切缘状态,采用logistic回归分析;并使用倾向评分加权分析校正潜在选择偏倚。

主要发现

  • 倾向评分校正后,接受新辅助化疗与总生存无显著关联(HR 0.97;p=0.591)。
  • 接受新辅助化疗的患者pN0率更高(OR 5.03;p<0.001)。
  • 新辅助化疗患者的pN0率低于SWOG-8710试验中接受新辅助化疗的患者(13% vs 38%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性设计。
  • 关于化疗类型的详细信息有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is supported by results from several randomized control trials, including SWOG-8710. OBJECTIVE: To look at the effectiveness of NAC before RC in current real world practice in the USA. DESIGN, SETTING, AND PARTICIPANTS: We used the National Cancer Data Base (NCDB) to identify patients with nonmetastatic muscle-invasive urothelial carcinoma of the bladder who underwent RC between 2004 and 2012. INTERVENTION: Receipt of NAC before RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was overall survival (OS). Secondary endpoints were rates of complete pathologic response (pT0), positive pathologic lymph nodes (pN+), and margin status. Using a landmark analysis to adjust for an immortal-time bias, OS comparison was performed using Cox regression analysis. Furthermore, logistic regression models examining secondary outcomes were fitted. To adjust for potential selection bias, propensity score-weighted analyses were performed. RESULTS AND LIMITATIONS: Of 8732 patients who underwent RC, 1619 (19%) received NAC. Following propensity score adjustment, receipt of NAC was not associated with an OS benefit (hazard ratio 0.97; p=0.591). On secondary outcome analysis, higher pT0 rates (odds ratio 5.03; p<0.001) were recorded among patients who received NAC, although rates of pT0 were lower than for patients treated with NAC within the SWOG-8710 trial (13% vs 38%). Limitations include the retrospective design and limited details available regarding type of chemotherapy. CONCLUSIONS: Important baseline differences between patients from the SWOG-8710 trial and those in general urologic practice exist. After adjusting for immortal-time bias, we did not find a clear survival advantage of NAC before RC when compared to RC alone in current general urology practice in the USA. PATIENT SUMMARY: The benefit of chemotherapy before radical cystectomy is supported by few randomized control trials. In this study, using a large national data set from the USA we found that preoperative chemotherapy is not associated with a survival benefit in all patients in general urology practice. Hence, better selection criteria are needed to determine who will benefit the most from chemotherapy before radical cystectomy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna N, Trinh QD, Seisen T, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018. PMID: 31100232. doi:10.1016/j.euo.2018.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。